PridCor Therapeutics

PridCor Therapeutics is a biotechnology company focused on developing novel small molecule therapies for cardiovascular diseases, particularly heart failure. The company's research is based on the discovery that inhibiting G protein-coupled receptor kinase 2 (GRK2) can restore cardiac function and prevent the progression of heart disease. By targeting this specific signaling pathway, PridCor aims to provide a new mechanism of action for patients who do not respond adequately to current standard-of-care treatments. Founded as a spin-out from Duke University, the company leverages the expertise of leading cardiologists and molecular biologists. PridCor is currently advancing its lead candidates through pre-clinical development to establish a pipeline of heart-focused therapeutics.